| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.27 | 1e-06 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-06 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.27 | 2e-06 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |